These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15332541)

  • 1. [Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0].
    Kaba H; Fukuda H; Yamamoto S; Ohashi Y
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1187-92. PubMed ID: 15332541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of adverse events of amrubicin hydrochloride for pretreated lung cancer patients].
    Takase M; Maruoka H; Maeda R; Shibata K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1789-92. PubMed ID: 18030011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The grading of lymphedema in oncology clinical trials.
    Cheville AL; McGarvey CL; Petrek JA; Russo SA; Thiadens SR; Taylor ME
    Semin Radiat Oncol; 2003 Jul; 13(3):214-25. PubMed ID: 12903011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Toxicity of doxorubicin and cyclophosphamide (60 mg/600 mg/m2) in adjuvant chemotherapy for breast cancer].
    Tsutani Y; Saeki T; Aogi K; Ohsumi S; Takashima S
    Gan To Kagaku Ryoho; 2005 Jun; 32(6):809-13. PubMed ID: 15984521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there room for improvement in adverse event reporting in the era of targeted therapies?
    Edgerly M; Fojo T
    J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment].
    Shimizu T; Saijo N
    Nihon Rinsho; 2003 Jun; 61(6):937-42. PubMed ID: 12806939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
    Steinberg M
    Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adverse drug reaction criteria of the Japan Society for Cancer Therapy].
    Shibuya M
    Gan To Kagaku Ryoho; 1997 Nov; 24(14):2036-41. PubMed ID: 9388511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
    Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C;
    J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: comparison with radiation therapy alone.
    Ohno T; Kato S; Wakatsuki M; Noda SE; Murakami C; Nakamura M; Tsujii H
    Gynecol Oncol; 2006 Oct; 103(1):94-9. PubMed ID: 16527337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it.
    Gwede CK; Johnson DJ; Daniels SS; Trotti A
    J Oncol Manag; 2002; 11(2):15-21. PubMed ID: 11989815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronochemotherapy for cancer].
    Akazawa S
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1191-202. PubMed ID: 9279336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0.
    Sakiyama M; Kami M; Hori A; Imataki O; Hamaki T; Murashige N; Kobayashi K; Kishi Y; Kojima R; Kim SW; Kusumi E; Yuji K; Miyakoshi S; Mori S; Tanosaki R; Taniguchi S; Takaue Y;
    Bone Marrow Transplant; 2004 Nov; 34(9):787-94. PubMed ID: 15361909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical study of fluorouracil.
    Nadler SH; Moore GE
    Surg Gynecol Obstet; 1968 Dec; 127(6):1210-4. PubMed ID: 4882472
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse event reporting in publications compared with sponsor database for cancer clinical trials.
    Scharf O; Colevas AD
    J Clin Oncol; 2006 Aug; 24(24):3933-8. PubMed ID: 16921045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
    Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pavlovian conditioning of nausea and vomiting.
    Stockhorst U; Steingrueber HJ; Enck P; Klosterhalfen S
    Auton Neurosci; 2006 Oct; 129(1-2):50-7. PubMed ID: 16949885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
    Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.